Commentary
Video
Author(s):
E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses current standard therapeutics for patients with NRG1 fusion–positive pancreatic cancer.
NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers
FDA Grants Accelerated Approval to Zenocutuzumab for NRG1+ NSCLC and Pancreatic Adenocarcinoma
Tumor Treating Fields Plus Chemotherapy Improves OS in Unresectable Pancreatic Cancer
CM24 Plus Nivolumab and Chemo Displays Efficacy vs Chemo Alone in Metastatic PDAC
Targeted Therapies Remain Central to Ongoing Research in Pancreatic Cancer
Pancreatic Cancer Awareness Month Brings Attention to Growing Incidence and Treatment Advances
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS